Cited by 6,712Pancreatic and Hepatic Oncology ResearchCancer Treatment and PharmacologyPancreatitis Pathology and Treatment

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Open access

Von Hoff, Daniel D., Ervin, Thomas, Arena, Francis P., Chiorean, E. Gabriela, Infante, Jeffrey, Moore, Malcolm, Seay, Thomas, Tjulandin, Sergei A., Ma, Wen Wee, Saleh, Mansoor N., Harris, Marion, Reni, Michele, Dowden, Scot, Laheru, Daniel, Bahary, Nathan, Ramanathan, Ramesh K., Tabernero, Josep, Hidalgo, Manuel, Goldstein, David, Van Cutsem, Eric, Wei, Xinyu, Iglesias, Jose, Renschler, Markus F.·2013·New England Journal of Medicine

DOI 10.1056/nejmoa1304369PMC PMC4631139

Open this paper in CoChat — free account

Abstract

BACKGROUND: In a phase 1-2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial clinical activity was noted in patients with advanced pancreatic cancer. We conducted a phase 3 study of the efficacy and safety of the combination versus gemcitabine monotherapy in patients with metastatic pancreatic cancer. METHODS: We randomly assigned patients with a Karnofsky performance-status score of 70 or more (on a scale from 0 to 100, with higher scores indicating better performance status) to nab-paclitaxel (125 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks or gemcitabine monotherapy (1000 mg per square meter) weekly for 7 of 8 weeks (cycle 1) and then on days 1, 8, and 15 every 4 weeks (cycle 2 and subsequent cycles). Patients received the study treatment until disease progression. The primary end point was overall survival; secondary end points were progression-free survival and overall response rate. RESULTS: A total of 861 patients were randomly assigned to nab-paclitaxel plus gemcitabine (431 patients) or gemcitabine (430). The median overall survival was 8.5 months in the nab-paclitaxel-gemcitabine group as compared with 6.7 months in the gemcitabine group (hazard ratio for death, 0.72; 95% confidence interval [CI], 0.62 to 0.83; P<0.001). The survival rate was 35% in the nab-paclitaxel-gemcitabine group versus 22% in the gemcitabine group at 1 year, and 9% versus 4% at 2 years. The median progression-free survival was 5.5 months in the nab-paclitaxel-gemcitabine group, as compared with 3.7 months in the gemcitabine group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.58 to 0.82; P<0.001); the response rate according to independent review was 23% versus 7% in the two groups (P<0.001). The most common adverse events of grade 3 or higher were neutropenia (38% in the nab-paclitaxel-gemcitabine group vs. 27% in the gemcitabine group), fatigue (17% vs. 7%), and neuropathy (17% vs. 1%). Febrile neutropenia occurred in 3% versus 1% of the patients in the two groups. In the nab-paclitaxel-gemcitabine group, neuropathy of grade 3 or higher improved to grade 1 or lower in a median of 29 days. CONCLUSIONS: In patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate, but rates of peripheral neuropathy and myelosuppression were increased. (Funded by Celgene; ClinicalTrials.gov number, NCT00844649.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1304369

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
Self-citation
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Self-citation
Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer
Gradishar, W. J., Tjulandin, S., Davidson, N. G. P., Shaw, H., Desai, N. P., Bhar, P., Hawkins, M., & O’Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,159
Self-citation
Gemcitabine Plus nab -Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
Hoff, D. D. V., Ramanathan, R. K., Borad, M. J., Laheru, D. A., Smith, L. S., Wood, T. E., Korn, R. L., Desai, N. P., Trieu, V. N., Iglesias, J. L. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.5742 · Cited by 1,040
Self-citation
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Kindler, H. L., Niedzwiecki, D., Hollis, D. R., Sutherland, S., Schrag, D., Hurwitz, H. I., Innocenti, F., Mulcahy, M. F., O'Reilly, E. M., Wozniak, T. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1386 · Cited by 848
Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
Cunningham, D., Chau, I., Stocken, D. D., Valle, J. W., Smith, D. B., Steward, W. P., Harper, P., Dunn, J., Smith, C. T., West, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2446 · Cited by 822
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study
Chauffert, B., Mornex, F., Bonnetain, F., Rougier, P. R., Mariette, C., Bouché, O., Bosset, J.-F., Aparicio, T., Mineur, L., Azzedine, A., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn281 · Cited by 696
Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
Philip, P. A., Benedetti, J., Corless, C. L., Wong, R., O'Reilly, E. M., Flynn, P. J., Rowland, K. M., Atkins, J. N., Mirtsching, B. C., Rivkin, S. E., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7550 · Cited by 643

Show all 23 references

Sorted by citations

Items 201–300 of 1,022

Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment
Looi, C.-K., Chung, F. F., Leong, C., Wong, S. F., Rosli, R., & Mai, C. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1153-8 · Cited by 209
DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives
Perkhofer, L., Gout, J., Roger, É., de Almeida, F. K., Simões, C., Wiesmüller, L., Seufferlein, T. T. W., & Kleger, A. (2020) · Gut · doi:10.1136/gutjnl-2019-319984 · Cited by 207
Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer
Heßmann, E., Patzak, M. S., Klein, L., Chen, N., Kari, V., Ramu, I., Bapiro, T. E., Frese, K. K., Gopinathan, A., Richards, F. M., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-311954 · Cited by 205
Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma
Janky, R., Binda, M. M., Allemeersch, J., den broeck, A. V., Govaere, O., Swinnen, J. V., Roskams, T., Aerts, S., & Topal, B. (2016) · BMC Cancer · doi:10.1186/s12885-016-2540-6 · Cited by 204
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 208
A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients With New-Onset Diabetes
Boursi, B., Finkelman, B., Giantonio, B. J., Haynes, K., Rustgi, A. K., Rhim, A. D., Mamtani, R., & Yang, Y.-X. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.11.046 · Cited by 202
Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma
Xie, Y., Zhu, S., Zhong, M., Yang, M., Sun, X., Liu, J., Kroemer, G., Lotze, M. T., Zeh, H. J., Kang, R., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.07.036 · Cited by 201
The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer
Sun, Q., Zhang, B., Hu, Q., Qin, Y., Xu, W., Liu, W., Yu, X., & Xu, J. (2018) · Theranostics · doi:10.7150/thno.26546 · Cited by 201
Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study
Kamath, S. D., Kalyan, A., Kircher, S. M., Nimeiri, H. S., Fought, A. J., Benson, A. B., & Mulcahy, M. F. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0473 · Cited by 200
Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma
Noel, M., O’Reilly, E. M., Wolpin, B. M., Ryan, D. P., Bullock, A. J., Britten, C. D., Linehan, D. C., Belt, B. A., Gamelin, E. C., Ganguly, B., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-019-00830-3 · Cited by 199
Mechanisms of Taxane Resistance
Maloney, S., Spring, C., Morejon-Lasso, L., & Prosperi, J. (2020) · Cancers · doi:10.3390/cancers12113323 · Cited by 198
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer
Borad, M. J., Reddy, S. G., Bahary, N., Uronis, H. E., Sigal, D., Cohn, A. L., Schelman, W. R., Stephenson, J., Chiorean, E. G., Rosen, P. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7504 · Cited by 197
Self-citation
Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer
Cuneo, K. C., Morgan, M. A., Sahai, V., Schipper, M. J., Parsels, L. A., Parsels, J. D., Devasia, T. P., Al-Hawaray, M., Cho, C. S., Nathan, H., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00730 · Cited by 197
Role of the tumor microenvironment in pancreatic cancer
Murakami, T., Hiroshima, Y., Matsuyama, R., Homma, Y., Hoffman, R. M., & Endo, I. (2019) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12225 · Cited by 196
Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4
Hanley, C. J., Mellone, M., Ford, K., Thirdborough, S. M., Mellows, T., Frampton, S. J., Smith, D. M., Harden, E., Szyndralewiez, C., Bullock, M., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx121 · Cited by 195
Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer
Xiong, G., Liu, C., Yang, G., Feng, M., Xu, J., Zhao, F., You, L., Zhou, L., Zheng, L., Hu, Y., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0777-7 · Cited by 195
Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?
He, J. P., Blair, A. B., Groot, V. P., Javed, A. A., Burkhart, R. A., Gemenetzis, G., Hruban, R. H., Waters, K. M., Poling, J., Zheng, L., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002672 · Cited by 194
Self-citation
Current standards and new innovative approaches for treatment of pancreatic cancer
Conroy, T., Bachet, J., Ayav, A., Huguet, F., Lambert, A., Caramella, C., Maréchal, R., Laethem, J. V., & Ducreux, M. P. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.12.026 · Cited by 193
Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study
Mahalingam, D., Wilkinson, G., Eng, K. H., Fields, P., Raber, P. L., Moseley, J. L., Cheetham, K., Coffey, M. C., Nuovo, G. J., Kaliński, P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2078 · Cited by 193
An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy
Chen, Y., Xia, R., Huang, Y., Zhao, W., Li, J., Zhang, X., Wang, P., Venkataramanan, R., Fan, J., Xie, W., et al. (2016) · Nature Communications · doi:10.1038/ncomms13443 · Cited by 192
Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma
Latenstein, A. E. J., van der Geest, L. G., Bonsing, B. A., Koerkamp, B. G., Mohammad, N. H., de Hingh, I. H. J. T., de Meijer, V. E., Molenaar, I. Q., van Santvoort, H. C., van Tienhoven, G., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.11.002 · Cited by 192
Desmoplasia and Chemoresistance in Pancreatic Cancer
Schober, M., Jesenofsky, R., Faissner, R., Weidenauer, C., Hagmann, W., Michl, P., Heuchel, R. L., Haas, S., & Löhr, M. J. (2014) · Cancers · doi:10.3390/cancers6042137 · Cited by 190
Recent advances in nanoparticle-mediated drug delivery
Kumar, B. D., Jalodia, K., Kumar, P., & Gautam, H. K. (2017) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2017.07.019 · Cited by 189
Update on the management of pancreatic cancer: Surgery is not enough
Ansari, D., Gustafsson, A., & Andersson, R. E. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i11.3157 · Cited by 188
Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas
Katz, M. H. G., Ou, F., Herman, J. M., Ahmad, S. A., Wolpin, B. W., Marsh, R., Behr, S. C., Shi, Q., Chuong, M. D., Schwartz, L. H., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3441-z · Cited by 188
Pancreatic Adenocarcinoma Staging in the Era of Preoperative Chemotherapy and Radiation Therapy
Zins, M., Matos, C., & Cassinotto, C. (2018) · Radiology · doi:10.1148/radiol.2018171670 · Cited by 188
Walking the line: The fate of nanomaterials at biological barriers
Meng, H., Leong, W., Leong, K. W., Chen, C., & Zhao, Y. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.056 · Cited by 187
Molecular and cellular mechanisms of chemoresistance in pancreatic cancer
Adamska, A., Elaskalani, O., Emmanouilidi, A., Kim, M. K., Razak, N. B. A., Metharom, P., & Falasca, M. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.11.007 · Cited by 186
Autophagy as a therapeutic target in pancreatic cancer
Piffoux, M., Eriau, E., & Cassier, P. A. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01039-5 · Cited by 189
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
Portal, A., Pernot, S., Tougeron, D., Arbaud, C., Bidault, A. T., de la Fouchardière, C., Hammel, P. R., Lecomte, T., Dréanic, J., Coriat, R., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.328 · Cited by 184
Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
Shroff, R. T., Hendifar, A. E., McWilliams, R. R., Geva, R., Epelbaum, R., Rolfe, L., Goble, S. M., Lin, K., Biankin, A. V., Giordano, H., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00316 · Cited by 183
CircFOXK2 Promotes Growth and Metastasis of Pancreatic Ductal Adenocarcinoma by Complexing with RNA-Binding Proteins and Sponging MiR-942
Wong, C. H., Lou, U. K., Li, Y., Chan, S. L., TONG, J. H. M., To, K., & Chen, Y. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3268 · Cited by 182
Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
Kabacaoğlu, D., Ciecielski, K. J., Ruess, D. A., & Algül, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01878 · Cited by 181
CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma
Salvador-Barberó, B., Álvarez‐Fernández, M., Zapatero‐Solana, E., Bakkali, A. E., Menéndez, C., Lopez-Casas, P. P., Domenico, T. D., Xie, T., VanArsdale, T. L., Shields, D. J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.01.007 · Cited by 181
Self-citation
Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer
Rombouts, S. J. E., Vogel, J. A., van Santvoort, H. C., van Lienden, K. P., van Hillegersberg, R., Busch, O. R., Besselink, M. G., & Molenaar, I. Q. (2014) · British journal of surgery · doi:10.1002/bjs.9716 · Cited by 179
Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging
Tummers, W. S. F. J., Miller, S. E., Teraphongphom, N. T., Gomez, A. J., Steinberg, I., Huland, D. M., Hong, S., Kothapalli, S., Hasan, A., Ertsey, R. D., et al. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6453-2 · Cited by 179
Exosomes as Drug Carriers for Cancer Therapy
Pullan, J. E., Confeld, M. I., Osborn, J., Kim, J., Sarkar, K., & Mallik, S. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00104 · Cited by 179
Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial
Liu, Y., Guo, Y., Wu, Z., Feng, K., Tong, C., Wang, Y., Dai, H., Shi, F., Yang, Q., & Han, W. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2020.04.088 · Cited by 179
Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer HeterogeneityPreprint
Martin, J. D., Fukumura, D., Duda, D. G., Boucher, Y., & Jain, R. K. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a027094 · Cited by 179
Advances in patient-derived tumor xenografts: From target identification to predicting clinical response rates in oncology
Rosfjord, E. C., Lucas, J., Li, G., & Gerber, H. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.06.008 · Cited by 178
Biological Effects of Nanoparticles on Macrophage Polarization in the Tumor Microenvironment
Reichel, D., Tripathi, M., & Perez, J. M. (2018) · Nanotheranostics · doi:10.7150/ntno.30052 · Cited by 178
Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results
Reyngold, M., Parikh, P. J., & Crane, C. H. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1309-x · Cited by 178
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
Jesus‐Acosta, A. D., Sugar, E. A., O'Dwyer, P. J., Ramanathan, R. K., Hoff, D. D. V., Rasheed, Z. A., Zheng, L., Begum, A., Anders, R. A., Maitra, A., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0683-3 · Cited by 178
Self-citation
Survival of pancreatic cancer cells lacking KRAS function
Muzumdar, M. D., Chen, P.-Y., Dorans, K. J., Chung, K. M., Bhutkar, A., Hong, E., Noll, E. M., Sprick, M. R., Trumpp, A., & Jacks, T. (2017) · Nature Communications · doi:10.1038/s41467-017-00942-5 · Cited by 177
Pancreatic cancer: Stroma and its current and emerging targeted therapies
Kota, J., Hancock, J., Kwon, J. J., & Korc, M. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.12.035 · Cited by 177
JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer
Lu, C., Talukder, A. M., Savage, N. M., Singh, N., & Liu, K. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1291106 · Cited by 177
Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial
Chung, V., McDonough, S., Philip, P. A., Cardin, D., Wang-Gillam, A., Hui, L., Tejani, M. A., Seery, T. E., Dy, I. A., Al Baghdadi, T., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5383 · Cited by 176
Pancreas Cancer-Associated Weight Loss
Hendifar, A. E., Petzel, M. Q. B., Zimmers, T. A., Denlinger, C. S., Matrisian, L. M., Picozzi, V. J., & Rahib, L. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0266 · Cited by 178
Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer
Yu, M., Nguyen, N. D., Huang, Y., Lin, D., Fujimoto, T. N., Molkentine, J. M., Deorukhkar, A., Kang, Y., Lucas, F. A. S., Fernandes, C. J., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126915 · Cited by 176
Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)—a randomized phase II trial of the AIO pancreatic cancer group
Seufferlein, T. T. W., Uhl, W. H., Kornmann, M., Algül, H., Friess, H., König, A. O., Ghadimi, M. B., Gallmeier, E., Bartsch, D. K., Lutz, M. P., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.09.161 · Cited by 176
An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study
Nakamura, K., Zhu, Z., Roy, S., Jun, E., Han, H., Muñoz, R. M., Nishiwada, S., Sharma, G. G., Cridebring, D., Zenhausern, F., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.06.090 · Cited by 174
Barriers and opportunities in pancreatic cancer immunotherapy
Ju, Y., Xu, D., Liao, M.-M., Sun, Y., Bao, W.-D., Yao, F., & Ma, L. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00681-z · Cited by 174
Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma
Perri, G., Prakash, L., Qiao, W., Varadhachary, G. R., Wolff, R. A., Fogelman, D. R., Overman, M. J., Pant, S., Javle, M. M., Koay, E. J., et al. (2020) · JAMA Surgery · doi:10.1001/jamasurg.2020.2286 · Cited by 173
Phase II study of FOLFIRINOX for chemotherapy‐naïve Japanese patients with metastatic pancreatic cancer
Okusaka, T., Ikeda, M., Fukutomi, A., Ioka, T., Furuse, J., Ohkawa, S., Isayama, H., & Boku, N. (2014) · Cancer Science · doi:10.1111/cas.12501 · Cited by 172
Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities
Bournet, B., Buscail, C., Muscari, F., Cordelier, P., & Buscail, L. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.012 · Cited by 173
Hypoxia-Targeting, Tumor Microenvironment Responsive Nanocluster Bomb for Radical-Enhanced Radiotherapy
Huo, D., Liu, S., Zhang, C., He, J., Zhou, Z., Zhang, H., & Hu, Y. (2017) · ACS Nano · doi:10.1021/acsnano.7b04737 · Cited by 171
Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review
Picard, M., & Castells, M. (2014) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-014-8416-0 · Cited by 170
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial
Fuchs, C. S., Azevedo, S. J., Okusaka, T., Laethem, J. V., Lipton, L. R., Riess, H. B., Szczylik, C. A., Moore, M. J., Peeters, M., Bodoky, G., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv027 · Cited by 168
Self-citation
Targeting Multiple Effector Pathways in Pancreatic Ductal Adenocarcinoma with a G-Quadruplex-Binding Small Molecule
Marchetti, C., Zyner, K. G., Ohnmacht, S. A., Robson, M. P., Haider, S. M., Morton, J. P., Marsico, G., Vo, T. D., Laughlin, S., Ahmed, A. A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01781 · Cited by 168
Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma
Noonan, A. M., Farren, M. R., Geyer, S. M., Huang, Y., Tahiri, S., Ahn, D., Mikhail, S., Ciombor, K. K., Pant, S., Aparo, S., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.66 · Cited by 166
Strategies for Increasing Pancreatic Tumor Immunogenicity
Johnson, B. A., Yarchoan, M. M., Lee, V., Laheru, D. A., & Jaffee, E. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2318 · Cited by 166
Self-citation
Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer
He, S., Dong, G., Li, Y., Wu, S., Wang, W., & Sheng, C. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201915896 · Cited by 166
Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer
Cullis, J. E., Siolas, D., Avanzi, A., Barui, S., Maitra, A., & Bar‐Sagi, D. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0125 · Cited by 165
A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer
Hirooka, Y., Kasuya, H., Ishikawa, T., Kawashima, H., Ohno, E., Villalobos, I. B., Naoe, Y., Ichinose, T., Koyama, N., Tanaka, M., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4453-z · Cited by 165
Management of pancreatic cancer in the elderly
Higuera, O. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i2.764 · Cited by 164
Transcytosis - An effective targeting strategy that is complementary to “EPR effect” for pancreatic cancer nano drug delivery
Liu, X., Jiang, J., & Meng, H. (2019) · Theranostics · doi:10.7150/thno.38587 · Cited by 164
Pancreatic Adenocarcinoma: Treating a Systemic Disease With Systemic Therapy
Sohal, D. P. S., Walsh, R. M., Ramanathan, R. K., & Khorana, A. A. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju011 · Cited by 163
Self-citation
Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists
Beatty, G. L., Li, Y., & Long, K. B. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1270208 · Cited by 163
Regulation and function of autophagy in pancreatic cancer
Li, J., Chen, X., Kang, R., Zeh, H. J., Klionsky, D. J., & Tang, D. (2020) · Autophagy · doi:10.1080/15548627.2020.1847462 · Cited by 167
Role of pancreatic stellate cells in chemoresistance in pancreatic cancer
McCarroll, J. A., Naim, S., Sharbeen, G., Russia, N., Lee, J., Kavallaris, M., Goldstein, D., & Phillips, P. A. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00141 · Cited by 162
Self-citation
Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer
Macedo, F. I. B., Ryon, E. L., Maithel, S. K., Lee, R. M., Kooby, D. A., Fields, R. C., Hawkins, W. G., Williams, G., Maduekwe, U. N., Kim, H. J., et al. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000003468 · Cited by 162
Open-label, Phase I Study of Nivolumab Combined with nab -Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer
Wainberg, Z. A., Höchster, H. S., Kim, E. J.-H., George, B., Kaylan, A., Chiorean, E. G., Waterhouse, D. M., Guiterrez, M., Parikh, A. R., Jain, R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0099 · Cited by 162
Self-citation
Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance
Deng, Y., Xia, X., Zhao, Y., Zhao, Z., Martinez, C., Yin, W., Yao, J., Hang, Q., Wu, W.-C., Zhang, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27349-7 · Cited by 162
Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer
Mittal, A., Chitkara, D., Behrman, S. W., & Mahato, R. I. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.04.053 · Cited by 161
Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer
Ueno, H., Ikeda, M., Ueno, M., Mizuno, N., Ioka, T., Omuro, Y., Nakajima, T. E., & Furuse, J. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2972-3 · Cited by 161
Bone marrow mesenchymal stem cells-derived exosomes for penetrating and targeted chemotherapy of pancreatic cancer
Zhou, Y., Zhou, W., Chen, X., Wang, Q., Li, C., Chen, Q., Zhang, Y., Lü, Y., Ding, X., & Jiang, C. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.11.013 · Cited by 161
FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma
Sadot, E., Doussot, A., O'Reilly, E. M., Lowery, M. A., Goodman, K. A., Gian, R. K., Tang, L. H., Gönen, M., D'Angelica, M. I., DeMatteo, R. P., et al. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4647-4 · Cited by 160
Multifunctional Nanomaterials and Their Applications in Drug Delivery and Cancer Therapy
Srinivasan, M., Rajabi, M., & Mousa, S. A. (2015) · Nanomaterials · doi:10.3390/nano5041690 · Cited by 158
Doubly blind: a systematic review of gender in randomised controlled trials
Phillips, S. P., & Hamberg, K. (2016) · Global Health Action · doi:10.3402/gha.v9.29597 · Cited by 158
High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis: Mechanisms and a Phase I/IIa study
Polireddy, K., Dong, R., Reed, G. A., Yu, J., Chen, P., Williamson, S. K., Violet, P.-C., Pessetto, Z. Y., Godwin, A. K., Fan, F., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17568-8 · Cited by 158
New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma
Singh, R., & O'Reilly, E. M. (2020) · Drugs · doi:10.1007/s40265-020-01304-0 · Cited by 158
Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial
Tempero, M. A., Pelzer, U., O'Reilly, E. M., Winter, J. M., Oh, D., Li, C., Tortora, G., Chang, H.-M., Lopez, C. D., Bekaii‐Saab, T., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01134 · Cited by 158
Self-citation
Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer
Tjensvoll, K., Lapin, M., Buhl, T., Oltedal, S., Berry, K. S.-O., Gilje, B., Søreide, J. A., Javle, M. M., Nordgård, O., & Smaaland, R. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.11.012 · Cited by 157
HALO-109–301: a Phase III trial of PEGPH20 (with Pemcitabine and Nab-Paclitaxel) in Hyaluronic Acid-High Stage IV Pancreatic Cancer
Doherty, G. J., Tempero, M. A., & Corrie, P. G. (2017) · Future Oncology · doi:10.2217/fon-2017-0338 · Cited by 157
Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma
Golan, T., O'Kane, G. M., Denroche, R. E., Raitses‐Gurevich, M., Grant, R. C., Holter, S., Wang, Y., Zhang, A. X. W., Jang, G. H., Stossel, C., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.01.220 · Cited by 157
Caveolae-Mediated Endocytosis Is Critical for Albumin Cellular Uptake and Response to Albumin-Bound Chemotherapy
Chatterjee, M., Ben‐Josef, E., Robb, R. N., Vedaie, M., Seum, S., Thirumoorthy, K., Palanichamy, K., Harbrecht, M. T., Chakravarti, A., & Williams, T. M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0604 · Cited by 156
Overcoming key biological barriers to cancer drug delivery and efficacy
Kim, S. M., Faix, P. H., & Schnitzer, J. E. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.016 · Cited by 156
Phytosome complex of curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: Results of a prospective phase II trial
Pastorelli, D., Fabricio, A. S. C., Giovanis, P., D'Ippolito, S., Fiduccia, P., Soldà, C., Buda, A., Sperti, C., Bardini, R., Dalt, G. D., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.013 · Cited by 156
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma
Renouf, D. J., Loree, J. M., Knox, J. J., Topham, J. T., Kavan, P., Jonker, D. J., Welch, S. A., Couture, F., Lemay, F., Tehfe, M. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32591-8 · Cited by 156
A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer
Ozaka, M., Ishii, H., Sato, T. S., Ueno, M., Ikeda, M., Uesugi, K., Sata, N., Miyashita, K., Mizuno, N., Tsuji, K., et al. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3577-9 · Cited by 155
Multi-institutional Study of Carbon-ion Radiotherapy for Locally Advanced Pancreatic Cancer: Japan Carbon-ion Radiation Oncology Study Group (J-CROS) Study 1403 Pancreas
Kawashiro, S., Yamada, S., Okamoto, M., Ohno, T., Nakano, T., Shinoto, M., Shioyama, Y., Nemoto, K., Isozaki, Y., Tsuji, H., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.04.057 · Cited by 154
WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death
Fischer, M. M., Cancilla, B., Yeung, V. P., Cattaruzza, F., Chartier, C., Murriel, C. L., Cain, J., Tam, R., Cheng, C.-Y., Evans, J., et al. (2017) · Science Advances · doi:10.1126/sciadv.1700090 · Cited by 154
Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial
Reiss, K. A., Mick, R., Teitelbaum, U. R., O’Hara, M. H., Schneider, C. J., Massa, R. C., Karasic, T. B., Tondon, R., Onyiah, C., Gosselin, M. K., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00369-2 · Cited by 156
Evaluation of curcumin loaded chitosan/PEG blended PLGA nanoparticles for effective treatment of pancreatic cancer
Arya, G., Das, M., & Sahoo, S. K. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.03.101 · Cited by 153
iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery
Kang, S., Lee, S., & Park, S. (2020) · Polymers · doi:10.3390/polym12091906 · Cited by 139
An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts
Cho, S., Kang, W., Han, J. Y., Min, S., Kang, J., Lee, A., Kwon, J. Y., Lee, C., & Park, H. (2016) · Molecules and Cells · doi:10.14348/molcells.2016.2350 · Cited by 152
The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy
Passero, F. C., Grapsa, D., Syrigos, K., & Saif, M. W. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1192471 · Cited by 152
The Role of Nutritional Support for Cancer Patients in Palliative Care
Cotogni, P., Stragliotto, S., Ossola, M., Collo, A., Riso, S., & on behalf of the Intersociety Italian Working Group for Nutritional Support in Cancer (2021) · Nutrients · doi:10.3390/nu13020306 · Cited by 152
Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus
Eriksson, E., Milenova, I. E., Wenthe, J., Ståhle, M., Leja-Jarblad, J., Ullenhag, G. J., Dimberg, A., Moreno, R., Alemany, R., & Loskog, A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0285 · Cited by 151
Barriers and opportunities for gemcitabine in pancreatic cancer therapy
Beutel, A. K., & Halbrook, C. J. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00331.2022 · Cited by 150

Authors: Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., Harris, M., Reni, M., Dowden, S., Laheru, D., Bahary, N., Ramanathan, R. K., Tabernero, J., Hidalgo, M., Goldstein, D., Van Cutsem, E., Wei, X., Iglesias, J., & Renschler, M. F.
Affiliations: University of Washington (US)
Tennessee Oncology (US)
Princess Margaret Cancer Centre (CA)
Russian Cancer Research Center NN Blokhin (RU)
Translational Genomics Research Institute (US)
Georgia Cancer Specialists (US)
Sidney Kimmel Comprehensive Cancer Center (US)
University of Pittsburgh Medical Center (US)
Universitat Autònoma de Barcelona (ES)
Prince of Wales Hospital (AU)
Celgene (United States) (US)
Bionomics (Australia) (AU)
ORCID: Arena, Francis P.
Chiorean, E. Gabriela
Moore, Malcolm
Tjulandin, Sergei A.
Ma, Wen Wee
Saleh, Mansoor N.
Harris, Marion
Reni, Michele
Laheru, Daniel
Bahary, Nathan
Tabernero, Josep
Hidalgo, Manuel
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2013-10-31
Volume: 369
Issue: 18
Pages: 1691-1703
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1304369
PMC: PMC4631139
OpenAlex: W2165480504
Cited by: 6,712
References: 23
Citations by year: 2026: 403 · 2025: 491 · 2024: 537 · 2023: 607 · 2022: 614 · 2021: 695 · 2020: 631 · 2019: 531 · 2018: 548 · 2017: 512 · 2016: 423 · 2015: 424 · 2014: 271 · 2013: 15
FWCI: 200.89
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (P30CA006973)
Topics: Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Keywords: pancreatic cancer, metastatic pancreatic cancer, nab-paclitaxel, gemcitabine, combination chemotherapy, gemcitabine monotherapy, overall survival, progression-free survival, overall response rate, treatment safety, adverse events, chemotherapy schedule, Karnofsky performance status
MeSH terms: Gemcitabine, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Albumins, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Female, Humans, Male, Middle Aged, Nervous System Diseases, Neutropenia, Pancreatic Neoplasms, Paclitaxel, Disease-Free Survival, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks